This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Where the Selloff Isn't Over

This column was originally published on RealMoney on June 1 at 1:30 p.m. EDT. It's being republished as a bonus for TheStreet.com readers.

It is an absolutely awful sign about a company if, after the recent broad selloff, insiders are still selling shares. At best, it indicates a lack of faith that the stock will recover soon. At worst, it could be a sign that executives are afraid that they had better get out now before shares fall even more. These are stocks that I'd suggest investors forget about bottom-feeding on. A little leg work could even uncover a decent short-selling opportunity.

Unlike the recent buy-side activity of insiders, which shows a couple of trends, the sellers are spread over several industries. Although biotech and technology are well-represented in the selling, those sectors also had some noticeable buying as well, so any red flags that appear are likely company-specific.

Shares of United Therapeutics (UTHR) started to slump before the market selloff after accounting changes reduced first-quarter profits. The technical condition of the stock has been steadily breaking down since. After a four-year run that took shares from $10 to nearly $80, United Therapeutics' 50-day moving average recently crossed below its 200-day average.

The heavy insider selling over the past few years -- particularly option-related selling -- was unremarkable, given its strong performance. But the fact that insiders have continued to sell with their stock now 35% below its recent highs tells me that they don't believe new highs will be seen any time soon.

Shares of Onyx Pharmaceuticals (ONXX) also are off by nearly a third over the past three months, but that hasn't dampened the enthusiasm of executives to flip their options for a risk-free profit. Even recent upgrades of Onyx by Wachovia and Prudential don't appear to have halted the slide.

Corporate spokesmen sometimes argue that options-related selling isn't really meaningful. Don't fall for that line. If executives really thought it likely that their shares were going to rebound from the depths, they would postpone the exercise. Options do not stymie an executive's free will.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,380.41 +263.17 1.63%
S&P 500 1,886.76 +24.00 1.29%
NASDAQ 4,258.4380 +41.0480 0.97%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs